{"id":"https://openalex.org/W1920546146","doi":"https://doi.org/10.1200/jco.1999.17.11.3431","title":"Phase II Trial of N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and Doxorubicin Chemotherapy in Metastatic Breast Cancer: A National Cancer Institute of Canada Clinical Trials Group Study","display_name":"Phase II Trial of N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and Doxorubicin Chemotherapy in Metastatic Breast Cancer: A National Cancer Institute of Canada Clinical Trials Group Study","publication_year":1999,"publication_date":"1999-11-01","ids":{"openalex":"https://openalex.org/W1920546146","doi":"https://doi.org/10.1200/jco.1999.17.11.3431","mag":"1920546146","pmid":"https://pubmed.ncbi.nlm.nih.gov/10550138"},"language":"en","primary_location":{"id":"doi:10.1200/jco.1999.17.11.3431","doi":"https://doi.org/10.1200/jco.1999.17.11.3431","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.1999.17.11.3431","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5008244196","display_name":"Kah Seng Khoo","orcid":"https://orcid.org/0000-0003-1199-3573","observed_orcids":["https://orcid.org/0000-0003-1199-3573"]},"institutions":[{"id":"https://openalex.org/I204722609","display_name":"Queen's University","ror":"https://ror.org/02y72wh86","country_code":"CA","type":"education","lineage":["https://openalex.org/I204722609"]},{"id":"https://openalex.org/I4210110605","display_name":"Bristol-Myers Squibb (Canada)","ror":"https://ror.org/01r00g076","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210110605"]},{"id":"https://openalex.org/I4405267856","display_name":"Canadian Cancer Trials Group","ror":"https://ror.org/04rg46g58","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405267856"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"K. Khoo","raw_affiliation_strings":["From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT","institution_ids":["https://openalex.org/I204722609","https://openalex.org/I4210110605","https://openalex.org/I4405267856"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111602453","display_name":"L. J. Brandes","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I204722609","display_name":"Queen's University","ror":"https://ror.org/02y72wh86","country_code":"CA","type":"education","lineage":["https://openalex.org/I204722609"]},{"id":"https://openalex.org/I4210110605","display_name":"Bristol-Myers Squibb (Canada)","ror":"https://ror.org/01r00g076","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210110605"]},{"id":"https://openalex.org/I4405267856","display_name":"Canadian Cancer Trials Group","ror":"https://ror.org/04rg46g58","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405267856"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"L. Brandes","raw_affiliation_strings":["From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT","institution_ids":["https://openalex.org/I204722609","https://openalex.org/I4210110605","https://openalex.org/I4405267856"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028015088","display_name":"Leonard M. Reyno","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I204722609","display_name":"Queen's University","ror":"https://ror.org/02y72wh86","country_code":"CA","type":"education","lineage":["https://openalex.org/I204722609"]},{"id":"https://openalex.org/I4210110605","display_name":"Bristol-Myers Squibb (Canada)","ror":"https://ror.org/01r00g076","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210110605"]},{"id":"https://openalex.org/I4405267856","display_name":"Canadian Cancer Trials Group","ror":"https://ror.org/04rg46g58","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405267856"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"L. Reyno","raw_affiliation_strings":["From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT","institution_ids":["https://openalex.org/I204722609","https://openalex.org/I4210110605","https://openalex.org/I4405267856"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049232174","display_name":"Andrew Arnold","orcid":"https://orcid.org/0000-0002-8821-8527","observed_orcids":["https://orcid.org/0000-0002-8821-8527"]},"institutions":[{"id":"https://openalex.org/I204722609","display_name":"Queen's University","ror":"https://ror.org/02y72wh86","country_code":"CA","type":"education","lineage":["https://openalex.org/I204722609"]},{"id":"https://openalex.org/I4210110605","display_name":"Bristol-Myers Squibb (Canada)","ror":"https://ror.org/01r00g076","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210110605"]},{"id":"https://openalex.org/I4405267856","display_name":"Canadian Cancer Trials Group","ror":"https://ror.org/04rg46g58","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405267856"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"A. Arnold","raw_affiliation_strings":["From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT","institution_ids":["https://openalex.org/I204722609","https://openalex.org/I4210110605","https://openalex.org/I4405267856"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046359837","display_name":"Susan Faye Dent","orcid":"https://orcid.org/0000-0002-9183-9340","observed_orcids":["https://orcid.org/0000-0002-9183-9340"]},"institutions":[{"id":"https://openalex.org/I204722609","display_name":"Queen's University","ror":"https://ror.org/02y72wh86","country_code":"CA","type":"education","lineage":["https://openalex.org/I204722609"]},{"id":"https://openalex.org/I4210110605","display_name":"Bristol-Myers Squibb (Canada)","ror":"https://ror.org/01r00g076","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210110605"]},{"id":"https://openalex.org/I4405267856","display_name":"Canadian Cancer Trials Group","ror":"https://ror.org/04rg46g58","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405267856"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"S. Dent","raw_affiliation_strings":["From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT","institution_ids":["https://openalex.org/I204722609","https://openalex.org/I4210110605","https://openalex.org/I4405267856"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111703388","display_name":"Ted A. Vandenberg","orcid":"https://orcid.org/0000-0001-7858-3590","observed_orcids":["https://orcid.org/0000-0001-7858-3590"]},"institutions":[{"id":"https://openalex.org/I204722609","display_name":"Queen's University","ror":"https://ror.org/02y72wh86","country_code":"CA","type":"education","lineage":["https://openalex.org/I204722609"]},{"id":"https://openalex.org/I4210110605","display_name":"Bristol-Myers Squibb (Canada)","ror":"https://ror.org/01r00g076","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210110605"]},{"id":"https://openalex.org/I4405267856","display_name":"Canadian Cancer Trials Group","ror":"https://ror.org/04rg46g58","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405267856"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"T. Vandenberg","raw_affiliation_strings":["From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT","institution_ids":["https://openalex.org/I204722609","https://openalex.org/I4210110605","https://openalex.org/I4405267856"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062128184","display_name":"David Lebwohl","orcid":"https://orcid.org/0000-0002-4578-1977","observed_orcids":["https://orcid.org/0000-0002-4578-1977"]},"institutions":[{"id":"https://openalex.org/I204722609","display_name":"Queen's University","ror":"https://ror.org/02y72wh86","country_code":"CA","type":"education","lineage":["https://openalex.org/I204722609"]},{"id":"https://openalex.org/I4210110605","display_name":"Bristol-Myers Squibb (Canada)","ror":"https://ror.org/01r00g076","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210110605"]},{"id":"https://openalex.org/I4405267856","display_name":"Canadian Cancer Trials Group","ror":"https://ror.org/04rg46g58","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405267856"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"D. Lebwohl","raw_affiliation_strings":["From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT","institution_ids":["https://openalex.org/I204722609","https://openalex.org/I4210110605","https://openalex.org/I4405267856"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015545810","display_name":"Bryn Fisher","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I204722609","display_name":"Queen's University","ror":"https://ror.org/02y72wh86","country_code":"CA","type":"education","lineage":["https://openalex.org/I204722609"]},{"id":"https://openalex.org/I4210110605","display_name":"Bristol-Myers Squibb (Canada)","ror":"https://ror.org/01r00g076","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210110605"]},{"id":"https://openalex.org/I4405267856","display_name":"Canadian Cancer Trials Group","ror":"https://ror.org/04rg46g58","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405267856"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"B. Fisher","raw_affiliation_strings":["From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT","institution_ids":["https://openalex.org/I204722609","https://openalex.org/I4210110605","https://openalex.org/I4405267856"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103081894","display_name":"Elizabeth A. Eisenhauer","orcid":"https://orcid.org/0009-0006-1410-7820","observed_orcids":["https://orcid.org/0009-0006-1410-7820"]},"institutions":[{"id":"https://openalex.org/I204722609","display_name":"Queen's University","ror":"https://ror.org/02y72wh86","country_code":"CA","type":"education","lineage":["https://openalex.org/I204722609"]},{"id":"https://openalex.org/I4210110605","display_name":"Bristol-Myers Squibb (Canada)","ror":"https://ror.org/01r00g076","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210110605"]},{"id":"https://openalex.org/I4405267856","display_name":"Canadian Cancer Trials Group","ror":"https://ror.org/04rg46g58","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405267856"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"E. Eisenhauer","raw_affiliation_strings":["From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT","institution_ids":["https://openalex.org/I204722609","https://openalex.org/I4210110605","https://openalex.org/I4405267856"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.5014,"has_fulltext":false,"cited_by_count":17,"citation_normalized_percentile":{"value":0.59802442,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"17","issue":"11","first_page":"3431","last_page":"3437"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.7461000084877014,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.7461000084877014,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.14579999446868896,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.010300000198185444,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dppe","display_name":"dppe","score":0.6700000166893005},{"id":"https://openalex.org/keywords/doxorubicin","display_name":"doxorubicin","score":0.8629999756813049},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9629999995231628},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.7870000004768372},{"id":"https://openalex.org/keywords/drug-interactions","display_name":"drug interactions","score":0.3930000066757202},{"id":"https://openalex.org/keywords/cns-side-effects","display_name":"CNS side effects","score":0.5339999794960022},{"id":"https://openalex.org/keywords/motion-sickness","display_name":"motion sickness","score":0.6620000004768372},{"id":"https://openalex.org/keywords/hallucinations","display_name":"hallucinations","score":0.8519999980926514},{"id":"https://openalex.org/keywords/febrile-neutropenia","display_name":"febrile neutropenia","score":0.902999997138977},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.6959999799728394},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.5950000286102295}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9045922160148621},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.7241598963737488},{"id":"https://openalex.org/C2781303535","wikidata":"https://www.wikidata.org/wiki/Q18936","display_name":"Doxorubicin","level":3,"score":0.6298233270645142},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5964996814727783},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.556398868560791},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5499151349067688},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5309922695159912},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.5006504058837891},{"id":"https://openalex.org/C2776802502","wikidata":"https://www.wikidata.org/wiki/Q417589","display_name":"Anthracycline","level":4,"score":0.4704429507255554},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4455403685569763},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.4215099811553955},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.39423057436943054}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":false},{"descriptor_ui":"D002170","descriptor_name":"Canada","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006633","descriptor_name":"Histamine Antagonists","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006633","descriptor_name":"Histamine Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010647","descriptor_name":"Phenyl Ethers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.1999.17.11.3431","doi":"https://doi.org/10.1200/jco.1999.17.11.3431","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.1999.17.11.3431","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:10550138","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10550138","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":23,"referenced_works":["https://openalex.org/W1811956372","https://openalex.org/W1984254136","https://openalex.org/W1988832560","https://openalex.org/W1994801925","https://openalex.org/W2013311104","https://openalex.org/W2018296966","https://openalex.org/W2031749932","https://openalex.org/W2044912812","https://openalex.org/W2046667419","https://openalex.org/W2060545795","https://openalex.org/W2060855916","https://openalex.org/W2061375880","https://openalex.org/W2083607170","https://openalex.org/W2095382275","https://openalex.org/W2125347693","https://openalex.org/W2125637243","https://openalex.org/W2264414928","https://openalex.org/W2265968143","https://openalex.org/W2398595611","https://openalex.org/W2403998323","https://openalex.org/W2409414924","https://openalex.org/W2413906664","https://openalex.org/W2468538204"],"related_works":["https://openalex.org/W1988832560","https://openalex.org/W2523754477","https://openalex.org/W2149626092","https://openalex.org/W2264414928","https://openalex.org/W2025753970","https://openalex.org/W2265968143","https://openalex.org/W2090995652","https://openalex.org/W4234192215","https://openalex.org/W2950996920","https://openalex.org/W1971889314"],"abstract_inverted_index":{"PURPOSE:":[0],"This":[1],"multicenter":[2],"phase":[3,291],"II":[4],"trial":[5,271,293],"investigated":[6],"the":[7,15,42,78,103,108,151,163,166,246,256,280],"efficacy":[8],"and":[9,22,33,117,159,185,230],"toxicity":[10,141],"of":[11,14,44,73,107,131,153,165,183,203,232,244,255,266,279,294],"a":[12,129,259,284,289],"combination":[13],"novel":[16],"intracellular":[17],"histamine":[18],"antagonist,":[19],"N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl":[20],"(DPPE),":[21],"doxorubicin":[23,97,148,274,295,297],"in":[24,77,174,253,277,303],"patients":[25,137,192,197,233],"with":[26,59,96,114,147,150,180,217,234],"anthracycline-na\u00efve":[27,60],"metastatic":[28,61,81],"breast":[29,62],"cancer.":[30],"Preclinical":[31],"models":[32],"early":[34],"single":[35],"institutional":[36],"studies":[37],"suggested":[38],"DPPE":[39,85,109,299],"could":[40],"potentiate":[41],"cytotoxicity":[43],"doxorubicin.":[45],"PATIENTS":[46],"AND":[47],"METHODS:":[48],"Forty-two":[49],"women,":[50],"32":[51],"to":[52,144,215],"77":[53],"years":[54],"old":[55],"(median,":[56],"59":[57],"years),":[58],"cancer":[63],"were":[64,112,138,172],"treated.":[65],"Patients":[66,111],"may":[67],"have":[68],"had":[69],"one":[70,278],"previous":[71],"regimen":[72],"nonanthracycline":[74],"chemotherapy,":[75],"either":[76],"adjuvant":[79],"or":[80,200],"disease":[82,236],"treatment":[83,122,281],"setting.":[84,306],"(6":[86],"mg/kg)":[87],"was":[88,123,142,209],"administered":[89],"as":[90],"an":[91,115,175],"80":[92],"minute":[93],"intravenous":[94],"infusion":[95],"(60":[98],"mg/m(2))":[99],"given":[100,124],"intravenously":[101],"over":[102],"last":[104],"20":[105],"minutes":[106],"infusion.":[110,167],"premedicated":[113],"antiemetic":[116],"sedating":[118],"regimen.":[119],"The":[120,205,241],"DPPE/doxorubicin":[121,245],"every":[125],"21":[126],"days":[127],"for":[128],"maximum":[130],"seven":[132],"cycles.":[133],"RESULTS:":[134],"All":[135],"42":[136],"assessable.":[139],"Overall,":[140],"comparable":[143],"that":[145,258],"expected":[146],"alone,":[149],"exception":[152],"DPPE-related":[154],"motion":[155],"sickness,":[156],"mild":[157],"hallucinations,":[158],"cerebellar":[160],"signs":[161],"at":[162],"time":[164],"These":[168],"CNS":[169],"side":[170],"effects":[171,243],"manageable":[173],"ambulatory":[176],"care":[177],"setting,":[178],"improved":[179],"subsequent":[181],"cycles":[182,202],"treatment,":[184],"did":[186],"not":[187],"usually":[188],"require":[189],"hospitalization.":[190],"Four":[191],"developed":[193],"febrile":[194],"neutropenia.":[195],"Thirty-five":[196],"received":[198],"four":[199],"more":[201],"chemotherapy.":[204],"overall":[206],"response":[207,248,286],"rate":[208,249],"52.5%":[210,247],"(95%":[211],"confidence":[212],"interval,":[213],"36%":[214],"68%),":[216],"9.5%":[218],"complete":[219],"responses":[220,226],"(n":[221,227,237],"=":[222,228,238],"4),":[223],"43%":[224],"partial":[225],"18),":[229],"38%":[231],"stable":[235],"16).":[239],"CONCLUSION:":[240],"antitumour":[242],"seems":[250],"encouraging,":[251],"particularly":[252],"consideration":[254],"fact":[257],"recently":[260],"reported":[261],"randomized":[262,290],"National":[263],"Cancer":[264],"Institute":[265],"Canada":[267],"Clinical":[268],"Trials":[269],"Group":[270],"using":[272],"single-agent":[273],"60":[275],"mg/m(2)":[276],"arms":[282],"achieved":[283],"31%":[285],"rate.":[287],"Thus,":[288],"III":[292],"versus":[296],"plus":[298],"is":[300],"being":[301],"conducted":[302],"this":[304],"clinical":[305]},"counts_by_year":[{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2013,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}